{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:25Z","timestamp":1790957605825,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejim.2024.01.025","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T16:42:08Z","timestamp":1706287328000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The lowest well tolerated blood pressure: A personalized target for all?"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4135-8936","authenticated-orcid":false,"given":"Paolo","family":"Verdecchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-7985","authenticated-orcid":false,"given":"Fabio","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9877-0702","authenticated-orcid":false,"given":"Gianpaolo","family":"Reboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.01.025_bib0001","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0002","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3399\/bjgp20X708053","article-title":"Diagnosis and management of hypertension in adults: NICE guideline update 2019","volume":"70","author":"Jones","year":"2020","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.ejim.2024.01.025_bib0003","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0004","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2024.01.025_bib0005","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2024.01.025_bib0006","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/M16-1785","article-title":"Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the american college of physicians and the American academy of family physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0007","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cjca.2018.02.022","article-title":"Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children","volume":"34","author":"Nerenberg","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5694\/mja16.00526","article-title":"Guideline for the diagnosis and management of hypertension in adults - 2016","volume":"205","author":"Gabb","year":"2016","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejim.2024.01.025_bib0009","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S2213-8587(20)30062-0","article-title":"Cardiorenal risk reduction guidance in diabetes: can we reach consensus?","volume":"8","author":"Sattar","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0010","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJMsb1901642","article-title":"The magic of randomization versus the myth of real-world evidence","volume":"382","author":"Collins","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0011","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.amjmed.2017.01.004","article-title":"optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials","volume":"130","author":"Bangalore","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001293","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis","volume":"9","author":"Lv","year":"2012","journal-title":"PLOS Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2022.03.032","article-title":"Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis","volume":"101","author":"Reboldi","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0014","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2024.01.025_bib0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/HYPERTENSIONAHA.116.07608","article-title":"More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis","volume":"68","author":"Verdecchia","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0016","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.01.025_bib0017","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.01.025_bib0018","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/eurheartj\/ehv633","article-title":"Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial","volume":"37","author":"Mancia","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.025_bib0019","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0021","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/biomet\/70.3.659","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Gordon Lan","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.ejim.2024.01.025_bib0022","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0023","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0024","series-title":"Effects of intensive blood pressure lowering treatment in reducing risk of cardiovasvular events","author":"Li","year":"2023"},{"key":"10.1016\/j.ejim.2024.01.025_bib0025","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2024.01.025_bib0026","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2024.01.025_bib0027","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.01.025_bib0028","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/HYPERTENSIONAHA.116.07257","article-title":"Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials","volume":"67","author":"Kjeldsen","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0029","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/HYPERTENSIONAHA.117.10479","article-title":"Blood pressure measurement in SPRINT (systolic blood pressure intervention trial)","volume":"71","author":"Johnson","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0030","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehq328","article-title":"J-curve revisited: an analysis of blood pressure and cardiovascular events in the treating to new targets (TNT) trial","volume":"31","author":"Bangalore","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.025_bib0031","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M16-1754","article-title":"Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: a systematic review and meta-analysis","volume":"166","author":"Weiss","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0032","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/eurheartj\/ehq281","article-title":"Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve","volume":"31","author":"Zanchetti","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.025_bib0033","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"Lewis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0034","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(87)90231-5","article-title":"Benefits and potential harm of lowering high blood pressure","volume":"1","author":"Cruickshank","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.01.025_bib0035","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2009.05.073","article-title":"The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?","volume":"54","author":"Messerli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0036","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2009.06.043","article-title":"Hypertension and the \"J-curve\"","volume":"54","author":"Williams","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0037","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11886-003-0105-1","article-title":"The J-curve in hypertension","volume":"5","author":"Cruickshank","year":"2003","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ejim.2024.01.025_bib0038","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/HYPERTENSIONAHA.113.01018","article-title":"Aggressive blood pressure lowering is dangerous: the J-curve: con side of the arguement","volume":"63","author":"Verdecchia","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0039","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1161\/CIRCULATIONAHA.116.026687","article-title":"Systolic blood pressure trajectory, frailty, and all-cause mortality >80 years of age: cohort study using electronic health records","volume":"135","author":"Ravindrarajah","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.025_bib0040","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1198\/000313005X70371","article-title":"Illustrating the impact of a time-varying covariatewith an extended Kaplan-Meier estimator","volume":"59","author":"Snapinn","year":"2005","journal-title":"Am Stat"},{"key":"10.1016\/j.ejim.2024.01.025_bib0041","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.publhealth.20.1.145","article-title":"Time-dependent covariates in the Cox proportional-hazards regression model","volume":"20","author":"Fisher","year":"1999","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.ejim.2024.01.025_bib0042","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1161\/CIRCULATIONAHA.116.025322","volume":"135","author":"Bress","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.025_bib0043","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/CIRCULATIONAHA.115.019657","article-title":"Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: a post hoc analysis of the secondary prevention of small subcortical strokes (SPS3) randomized trial","volume":"133","author":"Peralta","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.025_bib0044","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.01.025_bib0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jamainternmed.2013.14764","article-title":"Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults","volume":"174","author":"Tinetti","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejim.2024.01.025_bib0046","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jacc.2016.07.754","article-title":"Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control","volume":"68","author":"McEvoy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0047","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/01.CIR.83.3.845","article-title":"Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle","volume":"83","author":"Polese","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.025_bib0048","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/HYP.0000000000000018","article-title":"Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American heart association, American college of cardiology, and American society of hypertension","volume":"65","author":"Rosendorff","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0049","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","article-title":"Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study","volume":"388","author":"Vidal-Petiot","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.01.025_bib0050","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/HYPERTENSIONAHA.119.12787","article-title":"Diastolic blood pressure J-curve phenomenon in a tertiary-care hypertension clinic","volume":"74","author":"Lip","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0051","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1097\/HJH.0000000000002128","article-title":"Achievement of target SBP without attention to decrease in DBP can increase cardiovascular morbidity in treated arterial hypertension: the Campania Salute Network","volume":"37","author":"Izzo","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2024.01.025_bib0052","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/eurheartj\/ehz225","article-title":"Low on-treatment diastolic blood pressure is not independently associated with increased cardiovascular risk: an analysis of the SPRINT trial","volume":"40","author":"Sobieraj","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.01.025_bib0053","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1161\/CIRCULATIONAHA.117.030848","article-title":"Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control","volume":"137","author":"Beddhu","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.01.025_bib0054","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/HYPERTENSIONAHA.114.04310","article-title":"Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease","volume":"65","author":"Verdecchia","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0055","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","article-title":"Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials","volume":"389","author":"Bohm","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.01.025_bib0056","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/08037051.2015.1106750","article-title":"No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: the VALUE trial","volume":"25","author":"Kjeldsen","year":"2016","journal-title":"Blood Press"},{"key":"10.1016\/j.ejim.2024.01.025_bib0057","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.01.025_bib0058","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0059","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2021.02.058","article-title":"Patient selection for intensive blood pressure management based on benefit and adverse events","volume":"77","author":"Bress","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0060","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2018.01.074","article-title":"Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension","volume":"71","author":"Phillips","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0061","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamacardio.2021.3187","article-title":"Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial","volume":"6","author":"Berry","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0062","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1016\/j.jacc.2016.05.005","article-title":"No such thing as ideal blood pressure: a case for personalized medicine","volume":"67","author":"Fuster","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0063","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK prospective diabetes study group","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2024.01.025_bib0064","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","article-title":"Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study","volume":"13","author":"Schrier","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2024.01.025_bib0065","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2024.01.025_bib0066","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.01.025_bib0067","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1291\/hypres.31.2115","article-title":"Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS)","volume":"31","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ejim.2024.01.025_bib0068","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(09)61340-4","article-title":"Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial","volume":"374","author":"Verdecchia","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.01.025_bib0069","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.146035","article-title":"Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study","volume":"56","author":"Ogihara","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.01.025_bib0070","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/hr.2012.125","article-title":"Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure","volume":"35","author":"Asayama","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ejim.2024.01.025_bib0071","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jch.12094","article-title":"Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years","volume":"15","author":"Wei","year":"2013","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.ejim.2024.01.025_bib0072","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","article-title":"Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial","volume":"382","author":"Benavente","year":"2013","journal-title":"Lancet"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T19:00:05Z","timestamp":1715108405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":72,"alternative-id":["S0953620524000323"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.01.025","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The lowest well tolerated blood pressure: A personalized target for all?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}